CellSeed Inc.
Stock Price Chart
2026/08/03 UpdatedPrice Trend
2026/08/03 UpdatedPrice & Trading Details
2026/08/03 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥126M | ¥190M | ¥193M | ¥84M |
| Gross Profit | ¥61M | ¥107M | ¥110M | ¥43M |
| Operating Income | -¥743M | -¥698M | -¥846M | -¥1,046M |
| Pretax Income | -¥758M | -¥844M | -¥855M | -¥1,100M |
| Net Income | -¥760M | -¥847M | -¥860M | -¥1,104M |
| EPS | -¥36.31 | -¥29.43 | -¥25.72 | - |
| Operating Margin | -587.86% | -366.99% | -437.91% | -1,250.18% |
| Balance Sheet | ||||
| Total Assets | ¥1,544M | ¥2,466M | ¥2,433M | ¥1,656M |
| Total Equity | ¥1,178M | ¥2,165M | ¥2,163M | ¥1,268M |
| Total Liabilities | ¥366M | ¥301M | ¥270M | ¥387M |
| Cash | ¥1,072M | ¥2,163M | ¥2,134M | ¥1,319M |
| Interest-bearing Debt | ¥159M | ¥151M | ¥144M | ¥133M |
| Equity Ratio | 76.32% | 87.79% | 88.91% | 76.60% |
| D/E Ratio | 0.13 | 0.07 | 0.07 | 0.10 |
| Cash Flow | ||||
| Operating CF | -¥718M | -¥779M | -¥866M | -¥989M |
| Investing CF | ¥62M | ¥56M | -¥18M | -¥27M |
| Financing CF | ¥882M | ¥1,814M | ¥855M | ¥200M |
| Free CF | -¥734M | -¥801M | -¥884M | -¥1,016M |
| Efficiency | ||||
| ROE | -64.47% | -39.11% | -39.75% | -87.05% |
| ROA | -49.20% | -34.33% | -35.34% | -66.68% |
Latest IR Information
-
No. 25 Subscription Rights with Exercise Price Adjustment Provisions Monthly Exercise Status Notice
Discloses the monthly exercise status of stock option rights. For the target month, the number of shares issued is 104,600 shares, of which 1,046 rights were exercised (1.21% of the total issued 86,000). Unexercised stock options at month-end: 38,426 units....
Read more -
Notice on Monthly Exercise Status of New Stock Acquisition Rights (with Exercise Price Adjustment Clause) for the 25th Term
Read more
Latest News (5 items)
Company Information
About
CellSeed Inc. engages in the cell sheet regenerative medicine business in Japan, the rest of Asia, and Europe. It operates through Regenerative Medicine Support Business and Cell Sheet Regenerative Medicine Business segments. The company is involved in commercializing regenerative medicine using cell sheets, which include autologous and allogeneic chondrocyte sheets. It also offers regenerative medicine contract services comprising contract development and manufacturing; contract manufacturing and consulting for specified cell-based products; and training and education in cell culturing technology services. In addition, the company provides UpCell, a temperature-responsive cell cultureware for cell sheet engineering; RepCell, a temperature-responsive cell cultureware for cell collection; HydroCell, a low cell binding cultureware; ThermoPlate III, a heating element made of a transparent glass plate; cellZscope, an automated cell monitoring system; and cell sheet support products. CellSeed Inc. was incorporated in 2001 and is headquartered in Koto, Japan.
